Intel Stock Rises on Chip-Manufacturing Deal, But Fundamentals Remain Unchanged

What happened

Intel announced a deal to accelerate its chip-manufacturing revival, sending shares higher. However, the DeepValue master report highlights that Q1 2026 revenue growth was driven by scarcity pricing, not volume, with DCAI server ASPs up 27% YoY but volumes down 5%. Foundry external revenue remains negligible at $174M, primarily from Altera reclassification, and Intel has yet to secure any significant external foundry customer. The deal likely refers to the previously disclosed $14.2B Ireland SCIP minority repurchase, which does not alter the fundamental thesis: the stock price already embeds a successful turnaround, but financials still show consolidated losses and heavy capex. Until DCAI volumes turn positive and external foundry wins materialize, the risk-reward remains unfavorable.

Implication

The announced deal does not alter the core thesis: Intel's recovery hinges on converting supply-constrained pricing into unit growth and securing a named external foundry customer. Without these proofs, the current valuation (EV/EBITDA 41x) is unsustainable. Investors should use strength to trim positions above $130 and wait for an attractive entry near $90, or until Q2/Q3 disclosures confirm volume and foundry progress.

Thesis delta

No change. The deal is already incorporated in the base case scenario (supply constraints persist). The bullish case requires a named external 18A customer, which is absent. The bear case becomes more likely if supply loosens and ASPs normalize without volume recovery.